Home » Newsletters » BioWorld Science

BioWorld Science

June 18, 2008

View Archived Issues

Selective immunoproteasome inhibition with PR-957 beneficial in models of rheumatoid arthritis

CBP-501 well tolerated alone and with cisplatin in phase I solid tumor studies

New phase I and II data on BIBW-2992 reported

Recent patents disclose new therapeutic agents for obesity and nutrition disorders

Efficacy of golimumab in rheumatoid arthritis demonstrated in phase III studies

Cogentus enrolls first European patient in pivotal phase III CGT-2168 trial

Exelixis and FDA agree on Special Protocol Assessment for XL-184 phase III trial

Metabolex completes patient enrollment in phase II MBX-8025 trial

JX-594 well tolerated, active in refractory primary and metastatic liver cancer

CSL receives Australian approval to register Panvax avian flu vaccine

Novartis withdraws MAA for pre-pandemic vaccine Aflunov

Humira subcutaneous injection now available in Japan for rheumatoid arthritis

ARYx Therapeutics commences phase II/III trial comparing ATI-5923 to warfarin

Genzyme files Mozobil marketing applications in the United States and Europe

Oncothyreon initiates phase I PX-866 trial in patients with solid tumors

Adventrx reports CoFactor phase IIb overall survival results

Obese patients treated with liraglutide for 1 year show significant weight loss

Elan and Wyeth present top-line results from phase II bapineuzumab trial in AD

Lipoxen is granted Canadian approval to initiate phase I trial of ErepoXen for anemia

Takeda requests reexamination of negative opinion for ramelteon given by EMEA's CHMP

Bayer Yakuhin and Mitsubishi Tanabe enter joint marketing agreement for Glucobay

Novel antibacterial agents disclosed in recent Actelion patent

Recent Concert patent reports new anti-HIV agents

Spectrum selects Fusilev as tradename for levoleucovorin for injection

FDA Advisory Committee recommends approval of ustekinumab

Pharming reports positive results from North American trial of Rhucin in HAE

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...